
Related articles


Case study: ICON and Medable drive 85% eConsent adoption in U.S. menopause study
How do you drive adoption in a complex women’s health study? See how ICON and Medable reached 85% eConsent uptake across 1,200+ participants with a smarter, site-first approach.


Medable oncology solutions
Discover how Medable’s AI-powered oncology platform simplifies complex cancer trials by integrating eCOA, ePRO, and eConsent solutions—reducing trial time, improving patient retention, and enhancing data quality for faster, more efficient research.


Case study: Driving a high-adherence LTFU trial without an EDC
Learn how Medable is powering a decade-long, global long-term follow-up (LTFU) obesity study, achieving an impressive 97% patient retention rate without using a traditional EDC system all while delivering a compliant, scalable, and cost-efficient solution.



